JPH0338244B2 - - Google Patents
Info
- Publication number
- JPH0338244B2 JPH0338244B2 JP11780684A JP11780684A JPH0338244B2 JP H0338244 B2 JPH0338244 B2 JP H0338244B2 JP 11780684 A JP11780684 A JP 11780684A JP 11780684 A JP11780684 A JP 11780684A JP H0338244 B2 JPH0338244 B2 JP H0338244B2
- Authority
- JP
- Japan
- Prior art keywords
- polyvalent metal
- water
- amino acid
- plaster
- poultice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229910052751 metal Inorganic materials 0.000 claims description 30
- 239000002184 metal Substances 0.000 claims description 30
- 229940024606 amino acid Drugs 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 239000011505 plaster Substances 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 15
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 claims description 11
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 claims description 11
- 229920003169 water-soluble polymer Polymers 0.000 claims description 6
- LVBRFZFUCKKGDJ-HJWRJIQTSA-J magnesium;dipotassium;(2s)-2-aminobutanedioate;hydron Chemical compound [Mg+2].[K+].[K+].OC(=O)[C@@H](N)CC([O-])=O.OC(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O LVBRFZFUCKKGDJ-HJWRJIQTSA-J 0.000 claims 1
- 229940111263 potassium magnesium aspartate Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 230000014759 maintenance of location Effects 0.000 description 14
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 14
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 10
- 108010010803 Gelatin Proteins 0.000 description 10
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 10
- -1 alkaline earth metal salts Chemical class 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 229920000159 gelatin Polymers 0.000 description 10
- 239000008273 gelatin Substances 0.000 description 10
- 235000019322 gelatine Nutrition 0.000 description 10
- 235000011852 gelatine desserts Nutrition 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 10
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 10
- 229920000053 polysorbate 80 Polymers 0.000 description 10
- 239000005995 Aluminium silicate Substances 0.000 description 9
- 235000012211 aluminium silicate Nutrition 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 9
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 9
- 229940068968 polysorbate 80 Drugs 0.000 description 9
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 229920001577 copolymer Polymers 0.000 description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
- SWHAQEYMVUEVNF-UHFFFAOYSA-N magnesium potassium Chemical compound [Mg].[K] SWHAQEYMVUEVNF-UHFFFAOYSA-N 0.000 description 8
- 229940068988 potassium aspartate Drugs 0.000 description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 229960001047 methyl salicylate Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 239000000600 sorbitol Substances 0.000 description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 229960002389 glycol salicylate Drugs 0.000 description 5
- 229910021645 metal ion Inorganic materials 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 5
- 239000011787 zinc oxide Substances 0.000 description 5
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000002568 Capsicum frutescens Nutrition 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004898 kneading Methods 0.000 description 3
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 3
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- 235000019477 peppermint oil Nutrition 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 238000007711 solidification Methods 0.000 description 3
- 230000008023 solidification Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 229920002085 Dialdehyde starch Polymers 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000010642 eucalyptus oil Substances 0.000 description 2
- 229940044949 eucalyptus oil Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 235000020721 horse chestnut extract Nutrition 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 2
- 229920001083 polybutene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003902 salicylic acid esters Chemical class 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical group C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- ZUGAOYSWHHGDJY-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-aluminabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Al+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZUGAOYSWHHGDJY-UHFFFAOYSA-K 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004593 Epoxy Chemical class 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001247145 Sebastes goodei Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- UKNGDQSYPNBJAO-UHFFFAOYSA-N Tiaramide hydrochloride Chemical compound Cl.C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 UKNGDQSYPNBJAO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HDYRYUINDGQKMC-UHFFFAOYSA-M acetyloxyaluminum;dihydrate Chemical compound O.O.CC(=O)O[Al] HDYRYUINDGQKMC-UHFFFAOYSA-M 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 1
- 229940009827 aluminum acetate Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007130 inorganic reaction Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N isomenthone Natural products CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940116257 pepper extract Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Description
本発明は保水性、保形性に優れたパツプ剤に関
する。
水性膏体を用いたパツプ剤は、打ち身、捻挫等
の発熱を伴なう局所の急性炎症に対し、吸熱作用
（湿布）によつて炎症を抑制し、苦痛を和らげる
と共に、含まれる水の作用によつて薬効成分の皮
膚浸透を促進し、治療効果を高める有用な剤型で
ある。このようなパツプ剤としては、保水性に優
れ、含水率が高く、かつ固化、離水、裏じみ等が
生じないこと、保形性に優れ、だれ等が生じない
こと、適度な粘着性を有し、適時簡便に貼るだけ
ですぐに使用できることなどの特性を有している
ことが望ましい。
従来のパツプ剤は、カオリン、ゼラチン、グリ
セリンをベースとしてこれにポリアクリル酸ナト
リウム、カルボキシメチルセルロースナトリウム
等の他の水溶性高分子物質、有効成分、水などを
加えて練合し、ペースト状或いは餅状とした膏体
を布等の支持体に塗布したもので、通常保水性を
高めるためにグリセリン、プロピレングリコー
ル、ソルビトール等の多価アルコール、尿素や、
吸湿性、潮解性の高い塩化マグネシウム等のアル
カリ土類金属塩などを膏体に配合すると共に、保
形性を高めるために水溶性高分子物質を多価金属
イオン、アルデヒド類、エポキシ化合物等により
架橋化することが行なわれている。
しかしながら、保水性と保形性とは互に相反す
る性質のものであり、保水性を高めると保形性が
低下し、逆に保形性を高めると保水性が低下して
固化、離水、裏じみが生じたり、粘着力が低下す
る傾向があり、保水性と保形性の両者をバランス
良く高めることは困難である。しかも、保形性を
高めるために水溶性高分子物質を多価金属塩で架
橋する場合、一般に高分子物質（電解質）の金属
イオンの反応は無機反応に属し、その速度は極め
て速く、金属塩（特に可溶性塩の場合）添加と同
時に反応が生じるため、部分的に不均一な架橋ゲ
ル化（フロツキユレーシヨン）が生じて均一な膏
体が得られなかつたり、膏体の支持体に対する塗
布工程中で粘度上昇が著しく、均一に塗布できな
い等の問題がある。
また、従来のパツプ剤膏体はPHが６以上、通常
７〜９であるため、サリチル酸エステル類等の有
効成分の安定性が悪く、また皮膚刺激性を有する
等の問題がある。このため、酸性の膏体が望まれ
るが、従来のパツプ剤では、有効成分安定化や皮
膚刺激緩和等のために酒石酸、クエン酸等の有機
酸又は塩酸等の鉱酸を加えてPHを下げて酸性にす
ると、配合高分子物質（特にゼラチンやアニオン
性高分子物質）の粘度が著しく低下してダレや裏
じみを生じ、従つて酸性のパツプ剤においてはダ
レを防止するためによほどしつかりと架橋ゲル化
させなければならないが、従来技術ではPH６以下
にするとジアルデヒドデンプンや尿素は反応が進
行せず、金属架橋では架橋効果が少なかつたり、
架橋剤を加えれば加えるほど膏体自身は硬くなる
が、裏じみはかえつて多く生じることがあり、酸
性のパツプ剤を得ることは極めて困難であつた。
本発明者らは、上記事情に鑑み、保水性、保形
性に優れ、季節変化に伴なう温度、湿度の変化に
影響されることなく長期に亘り膏体が常に適度な
水分、稠度、風合、粘弾性、粘着性を有し、かつ
貼付中においても体温、発汗等によつて短期間に
水分含量が増減せず、従つて乾燥したり、逆に吸
湿軟化していわゆるだれ、べつとつき現象を起こ
すことのないパツプ剤を得るために鋭意研究を行
なつた結果、水溶性高分子物質を含有する膏体に
対してアミノ酸の多価金属誘導体及び／又はアミ
ノ酸の多価金属塩を配合することにより、上記目
的が効果的に達成されることを知見した。
即ち、本発明者らは、ゼラチン、カルボキシメ
チルセルロースナトリウム、ポリアクリル酸ナト
リウム等の水溶性高分子物質を含有するパツプ剤
膏体に金属イオン供与体としてアミノ酸の多価金
属誘導体及び／又はアミノ酸の多価金属塩を配合
した場合、アミノ基、カルボキシル基等の水溶性
高分子物質の官能基が多価金属イオンと結合或い
はキレーシヨンをし、水溶性高分子物質が架橋さ
れてより安定な構造配列を形成し、保水性、保形
性が向上すること、またカリミヨウバン等の無機
架橋剤を用いた場合と異なり、反応が緩やかで、
膏体製造中に急速に高分子物質と架橋化反応を起
こすことがなく、従つて部分的に硬化が生じて膏
体が不均一になつたり、急激な粘度上昇によつて
膏体を練合し難くなるというようなことがないこ
と、更に架橋剤としてジアルデヒドデンプンを用
いた場合と異なり、酸性領域においても高分子物
質との架橋反応が進行するため、酸性の膏体を得
ることができると共に、架橋剤として水酸化アル
ミニウムを用いた膏体の如くそのPHが加熱劣化や
保存に伴ない徐々に上昇して弱アルカリ性になる
ことがなく、このため膏体を製造時、保存時のい
ずれも酸性に維持することができ、サリチル酸エ
ステル類等の有効成分の安定化や皮膚刺激性の緩
和に寄与すること、しかも配合する他の成分に影
響を与えたり、制約を生じさせたりすることがな
いことを知見し、本発明をなすに至つたものであ
る。
以下、本発明につき更に詳しく説明する。
本発明に係るパツプ剤は、水溶性高分子物質を
含有する膏体にアミノ酸の多価金属誘導体及び／
又はアミノ酸の多価金属塩を配合してなるもので
ある。
この場合、水溶性高分子物質としてはゼラチ
ン、ペクチン、ポリアクリル酸、ポリアクリル酸
塩、ポリビニルアルコール、ポリビニルピロリド
ン、ポリビニルピロリドン・ビニルアセテート共
重合体、ポリエチレンオキサイド、カルボキシメ
チルセルロースナトリウム、ヒドロキシプロピル
セルロース、メチルセルロース、エチルセルロー
ス、アルギン酸塩、キサンタンガム、アラビアガ
ム、トラガントガム、カラヤガム、メチルビニル
エーテル・無水マレイン酸共重合体等が挙げら
れ、本発明においては多価金属イオンと反応、架
橋するいずれの水溶性高分子物質でも使用するこ
とができる。なお、水溶性高分子物質の使用量は
特に制限されないが、通常パツプ剤膏体全体の１
〜20％（重量％、以下同じ）である。
また、アミノ酸の多価金属誘導体又はアミノ酸
の多価金属塩の多価金属としては、カルシムウ、
マグネシウム、アルミニウム、鉄、バリウム、ビ
スマス等が使用できる。アミノ酸誘導体又はアミ
ノ酸としては、特に制限されないがα−アミノ酸
が好適に使用し得る。ここで、アミノ酸の多価金
属誘導体の種類は特に制限されないが、特にジヒ
ドロキシアルミニウムアミノアセテートが好適に
使用し得る。更に、アミノ酸の多価金属塩の種類
も特に制限されないが、特にアスパラギン酸マグ
ネシウムカリウムが好適に使用し得る。
なお、本発明においては、アミノ酸の多価金属
誘導体及びアミノ酸の多価金属塩としてはそれぞ
れの１種を単独で用いてもよく、２種以上を併用
しても差支えない。また、アミノ酸の多価金属誘
導体及び／又はアミノ酸の多価金属塩の配合量に
制限はないが、通常膏体全体の0.01〜10％特に
0.02〜２％とすることが好ましい。
更に、本発明の他の成分としては、通常使用さ
れる適宜な成分が用いられ、例えばプロピレング
リコール、ポリエチレングリコール、グリセリ
ン、ソルビトール等の１種又は２種以上の多価ア
ルコール（配合量通常膏体全体の５〜60％。５％
より少ないと保湿効果が不足し、また上限に特に
制限はないが、60％より多いと高分子の溶解性や
水の配合量が低下することがある。）、カオリン、
ベントナイト、モンモリロナイト、酸化亜鉛、酸
化チタン、無水ケイ酸等の１種又は２種以上の無
機粉体（配合量通常０〜30％。30％より多いと膏
体が硬くなりすぎ、肌へのフイツト感や粘着力が
低下することがある。）、水（配合量通常10〜80
％。10％より少ないと湿布効果が不足し、80％よ
り多いと膏体が軟化してダレが生じることがあ
る。）、サリチル酸メチル、サリチル酸グリコー
ル、インドメタシン、ｌ−メントール、ハツカ
油、ユーカリ油、dl−カンフル、ノニル酸ワニリ
ルアミド、ビタミンＥ、ジフエンヒドラミン、マ
レイン酸クロルフエニラミン、チモール、フルフ
エナム酸とその誘導体、メフエナム酸とその誘導
体、ジクロフエナツクナトリウム、アスピリン、
イブプロフエン、スリンダク、ナプロキセン、ピ
ロキシカム、塩酸チアラミド、フエンブフエン、
唐辛子エキス、唐辛子末、唐辛子チンキ、カプサ
イシン等の１種又は２種以上の有効成分（配合量
通常０〜20％）、膏体物性（柔軟性、粘着性、保
型性等）の調整剤としてグアガム、キサンタンガ
ム、アラビアガム、デンプン誘導体、ポリブテ
ン、ラテツクス、酢酸ビニルエマルシヨン、アク
リル樹脂エマルシヨン等の高分子物質、有効成分
の安定配合剤としてラノリン、流動パラフイン、
植物油、豚脂、牛脂、高級アルコール、高級脂肪
酸、活性剤等が必要に応じ適宜配合される。
本発明のパツプ剤は、上記各成分をよく練合し
てペースト状に調製し、これを紙、織布、不織
布、プラスチツクフイルム等の支持体（バツキン
グ）に塗布し、必要によりポリエチレンフイルム
等のフエイシングを被覆することにより得られる
ものである。
而して、本発明に係るパツプ剤は、水溶性高分
子物質を含有する膏体にアミノ酸の多価金属誘導
体及び／又はアミノ酸の多価金属塩を配合したこ
とにより、保水性、保形性に優れ、支持体に対す
る膏体のしみ出し（裏じみ）がなく、粘着性が高
いと共に、有効成分安定性に優れ、かつ皮膚刺激
性が緩和されたものである。
次に実施例及び比較列を示し、本発明を具体的
に説明する。
実施例１、比較例１
ジヒドロキシアルミニウムアミノアセテート
（グリシナール）１部（重量部、以下同じ）、カ
オリン（日局）７部、ポリアクリル酸ナトリウム
（アロンビスＳ）２部及びカルボキシメチルセ
ルロースナトリウム（CMCダイヤル1380）３
部を混合機内に入れ、これに濃グリセリン（日
局）25部を徐々に加えてペースト状になるまで充
分に撹拌して分散、混合する。別に、ゼラチン３
部を水54.5部で膨潤させて50〜60℃で均一液と
し、これを上記ペーストに加えて均一になるまで
練合する。これを35〜40℃になるまで冷却し、そ
の後界面活性剤（ポリソルベート80、日局）0.5
部及び薬効成分４部を加えて全体が均一になるま
で充分に練合する。なお、薬効成分４部はサリチ
ル酸メチル（日局）１部、ｌ−メントール（日
局）１部、dl−カンフル（日局）１部、マレイン
酸クロルフエニラミン（日局）0.5部及び酢酸ト
コフエロール（日局）0.5部からなるものである。
次に、これを展延機で不織布に一定の厚さに展延
し、表面をポリエチレンフイルムで覆い、一定の
面積に裁断した本発明パツプ剤を得、これをアル
ミニウム箔ラミネート袋に封入して製品とした。
上記の各工程においては、容易に基材の均一化
がなされ、練合に支障をきたすことはなかつた。
また、得られたパツプ剤は高温域で保存しても軟
化し難く、かつ貼付時の発汗によつても軟化し難
く、従つて形くずれ、だれ、べとつきが生じるこ
とがなく、長時間の貼付によつても冷感、密着
性、弾力性、柔軟性を失なわず、固化及び分離現
象も生じないものであつた。
次に、上記実施例１のパツプ剤におけるジヒド
ロキシアルミニウムアミノアセテート（アミノ酸
多価金属誘導体）配合の効果を調べるため、上記
組成のうちジヒドロキシアルミニウムアミノアセ
テートを除きその分を精製水で補なつた比較例１
のパツプ剤を製造し、下記試験により実施例１の
パツプ剤と比較例１のパツプ剤とを比較した。更
に、実施例１におけるジヒドロキシアルミニウム
アミノアセテート１部の代りに酢酸アルミニウム
１部を配合したもの（比較例２）、クエン酸アル
ミニウム1.6部を配合したもの（比較例３）を同
様にして製造した。その性状を第２表に示す。
試験方法
40±２℃、RH75％に調節した恒温恒湿器に各
パツプ剤をそれぞれ袋ごと入れ、２週間後に取り
出して室温に戻し、開封した後、膏体部分のはみ
出し、不織布への滲出（裏じみ）、ポリエチレン
フイルムを剥した時のフイルムへの膏体の付着、
ヒトの皮膚に貼付し、剥した時の皮膚への膏体の
付着をそれぞれ官能検査により評価した。結果を
下記第１表に示す。なお、評価基準は下記の通り
である。
評価基準
−：全くなし
±：わずかにあり
＋：少量あり
：多量にあり
：かなり多量にあり
The present invention relates to a poultice with excellent water retention and shape retention. A poultice using an aqueous plaster suppresses inflammation and relieves pain by absorbing heat (compress) for local acute inflammation accompanied by fever such as bruises and sprains, and the action of the water contained in it suppresses the inflammation. It is a useful dosage form that promotes skin penetration of medicinal ingredients and enhances therapeutic effects. Such poultices should have excellent water retention, high water content, no solidification, syneresis, bleeding, etc., excellent shape retention, no dripping, and appropriate adhesiveness. However, it is desirable that the adhesive has characteristics such as being able to be used immediately by simply pasting it on at the appropriate time. Conventional poultices are made by kneading kaolin, gelatin, and glycerin as a base with other water-soluble polymeric substances such as sodium polyacrylate and sodium carboxymethylcellulose, active ingredients, and water, and forming them into a paste or rice cake. It is a paste applied to a support such as cloth, and usually contains polyhydric alcohols such as glycerin, propylene glycol, sorbitol, urea, etc. to increase water retention.
In addition to incorporating alkaline earth metal salts such as magnesium chloride with high hygroscopicity and deliquescent properties into the plaster, water-soluble polymeric substances are mixed with polyvalent metal ions, aldehydes, epoxy compounds, etc. to improve shape retention. Crosslinking is performed. However, water retention and shape retention are mutually contradictory; increasing water retention reduces shape retention, and conversely, increasing shape retention decreases water retention, resulting in solidification, syneresis, and There is a tendency for bleeding to occur and adhesive strength to decrease, making it difficult to improve both water retention and shape retention in a well-balanced manner. Moreover, when a water-soluble polymer substance is crosslinked with a polyvalent metal salt to improve shape retention, the reaction of metal ions in the polymer substance (electrolyte) generally belongs to an inorganic reaction, and its speed is extremely fast. (Especially in the case of soluble salts) Since a reaction occurs simultaneously with the addition, partially non-uniform crosslinking gelation (flocculation) may occur, making it impossible to obtain a uniform paste or coating the paste on the support. There is a problem that the viscosity increases significantly during the process, making it impossible to apply it uniformly. Further, since conventional plasters have a pH of 6 or more, usually 7 to 9, they have problems such as poor stability of active ingredients such as salicylic acid esters and skin irritation. For this reason, acidic plasters are desired, but in conventional poultices, organic acids such as tartaric acid and citric acid or mineral acids such as hydrochloric acid are added to stabilize the active ingredients and alleviate skin irritation to lower the pH. When made acidic, the viscosity of the compounded polymer substances (especially gelatin and anionic polymer substances) decreases significantly, causing sag and bleed. However, in conventional technology, when the pH is lower than 6, the reaction of dialdehyde starch and urea does not proceed, and metal crosslinking has little crosslinking effect.
The more crosslinking agent is added, the harder the paste itself becomes, but more bleed may occur, making it extremely difficult to obtain an acidic poultice. In view of the above circumstances, the inventors of the present invention have developed a plaster that has excellent water retention and shape retention properties, and is capable of maintaining appropriate moisture content, consistency, and consistency over a long period of time without being affected by changes in temperature and humidity associated with seasonal changes. It has a texture, viscoelasticity, and adhesiveness, and its moisture content does not increase or decrease in a short period of time due to body temperature, perspiration, etc. even during application, so it may dry out or become soft after absorbing moisture, causing so-called sagging. As a result of intensive research to obtain a poultice that does not cause stickiness, we have found that polyvalent metal derivatives of amino acids and/or polyvalent metal salts of amino acids have been added to plasters containing water-soluble polymeric substances. It has been found that the above object can be effectively achieved by incorporating the following. That is, the present inventors added polyvalent metal derivatives of amino acids and/or polyvalent amino acids as metal ion donors to poultices containing water-soluble polymeric substances such as gelatin, sodium carboxymethyl cellulose, and sodium polyacrylate. When a valent metal salt is blended, the functional groups of the water-soluble polymer substance such as amino groups and carboxyl groups bond or chelate with the polyvalent metal ion, and the water-soluble polymer substance is crosslinked to create a more stable structural arrangement. In addition, unlike when using an inorganic crosslinking agent such as potassium alum, the reaction is gradual,
There is no rapid cross-linking reaction with polymeric substances during the production of the plaster, which prevents partial hardening and unevenness of the plaster, or a sudden increase in viscosity that prevents the plaster from being kneaded. Furthermore, unlike when dialdehyde starch is used as a crosslinking agent, the crosslinking reaction with the polymer substance proceeds even in an acidic region, making it possible to obtain an acidic paste. In addition, unlike plasters that use aluminum hydroxide as a crosslinking agent, the pH of the plaster does not gradually increase due to heat deterioration or storage and become weakly alkaline. It also maintains acidity, contributing to the stabilization of active ingredients such as salicylic acid esters and alleviation of skin irritation, and does not affect or impose restrictions on other ingredients. We have discovered that there is no such thing, and have come up with the present invention. The present invention will be explained in more detail below. The plaster according to the present invention contains a polyvalent metal derivative of an amino acid and/or a plaster containing a water-soluble polymeric substance.
Or it is made by blending a polyvalent metal salt of an amino acid. In this case, the water-soluble polymer substances include gelatin, pectin, polyacrylic acid, polyacrylate, polyvinyl alcohol, polyvinylpyrrolidone, polyvinylpyrrolidone/vinyl acetate copolymer, polyethylene oxide, sodium carboxymethylcellulose, hydroxypropylcellulose, and methylcellulose. , ethyl cellulose, alginate, xanthan gum, gum arabic, gum tragacanth, gum karaya, methyl vinyl ether/maleic anhydride copolymer, etc. In the present invention, any water-soluble polymeric substance that reacts with and crosslinks with polyvalent metal ions can be used. can be used. The amount of water-soluble polymer substance to be used is not particularly limited, but usually 1 part of the entire poultice is used.
~20% (weight%, same hereinafter). In addition, examples of polyvalent metals in polyvalent metal derivatives of amino acids or polyvalent metal salts of amino acids include calcium,
Magnesium, aluminum, iron, barium, bismuth, etc. can be used. The amino acid derivative or amino acid is not particularly limited, but α-amino acids can be preferably used. Here, the type of polyvalent metal derivative of amino acid is not particularly limited, but dihydroxyaluminum aminoacetate can be particularly preferably used. Further, the type of polyvalent metal salt of an amino acid is not particularly limited, but magnesium potassium aspartate can be particularly preferably used. In addition, in the present invention, each of the polyvalent metal derivatives of amino acids and the polyvalent metal salts of amino acids may be used alone, or two or more types may be used in combination. In addition, there is no limit to the amount of polyvalent metal derivatives of amino acids and/or polyvalent metal salts of amino acids, but it is usually 0.01 to 10% of the entire plaster.
It is preferably 0.02 to 2%. Furthermore, as other components of the present invention, appropriate components commonly used are used, such as one or more polyhydric alcohols such as propylene glycol, polyethylene glycol, glycerin, and sorbitol (in the amount usually 5-60% of the total.5%
If it is less than 60%, the moisturizing effect will be insufficient, and although there is no particular upper limit, if it is more than 60%, the solubility of the polymer and the amount of water mixed may decrease. ), kaolin,
One or more inorganic powders such as bentonite, montmorillonite, zinc oxide, titanium oxide, and silicic anhydride (compounding amount is usually 0 to 30%. If it exceeds 30%, the paste becomes too hard and does not fit well to the skin. ), water (compounding amount is usually 10 to 80%).
%. If it is less than 10%, the compressive effect will be insufficient, and if it is more than 80%, the plaster may become soft and sag. ), methyl salicylate, glycol salicylate, indomethacin, l-menthol, peppermint oil, eucalyptus oil, dl-camphor, nonylic acid vanillylamide, vitamin E, diphenhydramine, chlorpheniramine maleate, thymol, flufenamic acid and its derivatives , mefenamic acid and its derivatives, diclofenac sodium, aspirin,
ibuprofen, sulindac, naproxen, piroxicam, thiaramide hydrochloride, fenbufuene,
One or more active ingredients such as chili pepper extract, chili powder, chili tincture, capsaicin, etc. (compounding amount usually 0-20%), as an agent for adjusting the physical properties of the plaster (flexibility, adhesiveness, shape retention, etc.) Polymeric substances such as guar gum, xanthan gum, gum arabic, starch derivatives, polybutene, latex, vinyl acetate emulsion, acrylic resin emulsion, lanolin, liquid paraffin as a stabilizing agent for active ingredients,
Vegetable oil, lard, beef tallow, higher alcohol, higher fatty acid, activator, etc. are appropriately blended as necessary. The poultice of the present invention is prepared by thoroughly kneading the above-mentioned components into a paste, which is applied to a support (backing) such as paper, woven fabric, non-woven fabric, or plastic film, and if necessary, a paste such as polyethylene film. It is obtained by coating facings. Therefore, the poultice according to the present invention has improved water retention and shape retention by blending a polyvalent metal derivative of an amino acid and/or a polyvalent metal salt of an amino acid into a plaster containing a water-soluble polymeric substance. It has excellent adhesiveness, no bleeding of the paste onto the support, high adhesiveness, excellent stability of active ingredients, and reduced skin irritation. Next, examples and comparison columns will be shown to specifically explain the present invention. Example 1, Comparative Example 1 1 part of dihydroxyaluminum aminoacetate (glycinal) (parts by weight, same hereinafter), 7 parts of kaolin (JP), 2 parts of sodium polyacrylate (Aronbis S), and sodium carboxymethyl cellulose (CMC Dial 1380) )3
1 part into a mixer, and gradually add 25 parts of concentrated glycerin (Japanese Pharmacopoeia) to this, stirring thoroughly to disperse and mix until it becomes a paste. Separately, gelatin 3
1 part is swollen with 54.5 parts of water to form a homogeneous liquid at 50 to 60°C, and this is added to the above paste and kneaded until uniform. This is cooled to 35-40℃, and then a surfactant (polysorbate 80, JP) 0.5
1 part and 4 parts of the medicinal ingredient and knead thoroughly until the whole is homogeneous. The 4 parts of the medicinal ingredients are 1 part of methyl salicylate (Japanese Pharmacopoeia), 1 part of l-menthol (Japanese Pharmacopoeia), 1 part of dl-camphor (Japanese Pharmacopoeia), 0.5 part of chlorpheniramine maleate (Japanese Pharmacopoeia), and acetic acid. It consists of 0.5 parts of tocopherol (Japanese version).
Next, this was spread on a non-woven fabric to a certain thickness using a spreading machine, the surface was covered with a polyethylene film, the patch of the present invention was cut to a certain area, and this was sealed in an aluminum foil laminated bag. It was made into a product. In each of the above steps, the base material was easily made uniform, and the kneading was not hindered.
In addition, the resulting poultices do not easily soften even when stored at high temperatures, and do not easily soften due to sweating during application, so they do not lose their shape, sag, or become sticky, and can be used for long periods of time. It did not lose its cooling sensation, adhesion, elasticity, or flexibility, and neither solidification nor separation occurred even after exposure to water. Next, in order to investigate the effect of adding dihydroxyaluminum aminoacetate (amino acid polyvalent metal derivative) in the poultice of Example 1, a comparative example was prepared in which dihydroxyaluminum aminoacetate was removed from the above composition and the remaining amount was supplemented with purified water. 1
The following tests were conducted to compare the plaster of Example 1 and the plaster of Comparative Example 1. Furthermore, a product containing 1 part of aluminum acetate instead of 1 part of dihydroxyaluminum aminoacetate in Example 1 (Comparative Example 2) and a product containing 1.6 parts of aluminum citrate (Comparative Example 3) were produced in the same manner. Its properties are shown in Table 2. Test method: Each bag of each poultice was placed in a constant temperature and humidity chamber adjusted to 40±2℃ and RH75%, and after two weeks, it was taken out and brought to room temperature. bleed), adhesion of plaster to the polyethylene film when removed,
The adhesion of the paste to the skin when it was applied to human skin and removed was evaluated by a sensory test. The results are shown in Table 1 below. The evaluation criteria are as follows. Evaluation criteria -: Not at all ±: Slightly present +: A small amount present: A large amount present: Quite a large amount present
【表】
第１表の結果より、アミノ酸多価金属誘導体を
配合した本発明パツプ剤は、アミノ酸多価金属誘
導体を配合しない比較例のパツプ剤に比べて膏体
の凝集性、保形性、保水性等が高く、優れた特性
を有するものであることが認められた。[Table] From the results in Table 1, it is clear that the plaster of the present invention containing an amino acid polyvalent metal derivative has better cohesiveness and shape retention than the comparative plaster that does not contain an amino acid polyvalent metal derivative. It was recognized that it has excellent properties such as high water retention.
【表】
実施例２、比較例４
実施例１のパツプ剤の組成において、ジヒドロ
キシアルミニウムアミノアセテート１部を代りに
アスパラギン酸マグネシウムカリウム１部を配合
し、同様にして実施例２のパツプ剤を得た。ま
た、上記組成のうちアスパラギン酸マグネシウム
カリウムを除きその分を精製水で補なつた比較パ
ツプ剤を製造し、実施例１、比較例１におけると
同様に試験により実施例２のパツプ剤と比較例２
のパツプ剤とを比較した。結果を第３表に示す。[Table] Example 2, Comparative Example 4 In the composition of the poultice of Example 1, 1 part of magnesium potassium aspartate was added instead of 1 part of dihydroxyaluminum aminoacetate, and the poultice of Example 2 was obtained in the same manner. Ta. In addition, a comparative poultice was prepared by removing magnesium potassium aspartate from the above composition and supplementing it with purified water. 2
It was compared with a poultice. The results are shown in Table 3.
【表】
第３表の結果より、アミノ酸多価金属塩を配合
した本発明パツプ剤は、アミノ酸多価金属塩を配
合しない比較例のパツプ剤に比べて膏体の凝集
性、保形性、保水性等が高く、優れた特性を有す
るものであることが認められた。
実施例 ３
ジヒドロキシアルミニウムアミノアセテート
（グリシナール）0.2部、カオリン（日局）５
部、酸化チタン１部、ポリビニルピロリドン（Ｋ
−90）１部、ポリアクリル酸ナトリウム（ビスコ
メート）１部及びカルボキシメチルセルロース
ナトリウム（CMCダイセル2200）４部を混合
機内に入れ、これに濃グリセリン（日局）20部及
び70％ソルビトール液（日局）10部を加えてペー
スト状に均一分散するまで混合する。次に、ポリ
アクリル酸（ジユリマーAC）３部を水52.45部
に膨潤溶解した液を上記ペーストに加えてよく練
合する。その後、これに界面活性剤（ポリソルベ
ート80、日局）１部及び薬効成分1.35部を加えて
全体が均一に餅状となるまで練合する。なお、薬
効成分1.35部はサリチル酸グリコール（サリメン
ト）0.5部、dl−カンフル（日局）0.2部、ハツ
カ油（日局）0.3部、酢酸トコフエロール（日局）
0.3部及び塩酸ジフエンヒドラミン（日局）0.05
部からなるものである。次に、これを展延機で不
織布に一定の厚さに展延し、表面をポリエチレン
フイルムで覆い、一定の面積に裁断して本発明パ
ツプ剤を得、これをアルミニウム箔ラミネート袋
に封入して製品とした。
上記実施例３のパツプ剤を実施例１、比較例１
におけると同様の試験により調べたところ、やは
り膏体の凝集性、保形性、保水性等が高く、優れ
た特性を有するものであつた。なお、膏体のPHは
4.5で酸性であり、また実施例３のパツプ剤及び
実施例３のパツプ剤と同一薬効成分を同一含有量
で含む市販パツプ剤をそれぞれ50℃で10週間保存
した場合、市販パツプ剤のPHは保存前は5.3であ
つたのが6.3以上に上昇し、サリチル酸グリコー
ルが分解してその残存率がわずか10％となり、含
量低下が著しく認められたのに対し、実施例３の
パツプ剤のPHは4.5のまま変化がなく、サリチル
酸グリコールの残存率も93％でほとんど分解が認
められず、本発明パツプ剤は製造時、保存時のい
ずれにおいても酸性に維持されることにより、有
効成分を安定化させ得ることが認められた。
実施例 ４
ジヒドロキシアルミニウムアミノアセテート１％
アスパラギン酸マグネシウムカリウム 0.2％
カオリン 5.5％
酸化チタン 0.5％
ポリビニルアルコール ２％
ポリアクリル酸ナトリウム ５％
ポリビニルピロリドン・ビニルアセテート共重合
体 ６％
カルボキシビニルポリマー １％
濃グリセリン 24％
クエン酸 0.5％
ゼラチン ５％
ソルビタンモノオレエート １％
ポリオキシエチレンソルビタンモノオレエート
（ポリソルベート80） ２％
イソステアリン酸 ２％
ミリスチン酸イソプロピル ３％
スクワラン １％
ユーカリ油 ２％
インドメタシン １％水 残
合 計 100.0％
実施例 ５
ジヒドロキシアルミニウムアミノアセテート
0.5％
カオリン 12％
酸化亜鉛 ６％
ポリビニルアルコール ５％
ポリアクリル酸ナトリウム ９％
ポリビニルピロリドン・ビニルアセテート共重合
体 ４％
アルギン酸ナトリウム １％
ポリエチレングリコール400 ５％
70％ソルビトール液 16％
尿 素 １％
ゼラチン ８％
ポリソルベート80 １％
オウバクエキス 0.6％
セイヨウトチノキエキス 0.2％
ヒアルロン酸 １％
サリチル酸メチル １％
ｌ−メントール １％水 残
合 計 100.0％
実施例 ６
ジヒドロキシアルミニウムアミノアセテート
0.3％
アスパラギン酸マグネシウムカリウム １％
酸化亜鉛 １％
ポリビニルアルコール １％
ポリアクリル酸ナトリウム ４％
ポリビニルピロリドン・ビニルアセテート共重合
体 ２％
ヒドロキシプロピルセルロース ３％
サイクロデキストリン １％
濃グリセリン 18％
ヒマシ油 １％
プロピレングリコール ４％
クエン酸 ２％
ゼラチン ９％
ポリオキシエチレン硬化ヒマシ油 0.6％
ポリソルベート80 0.5％
サリチル酸メチル １％
サリチル酸グリコール 0.5％水 残
合 計 100.0％
実施例 ７
アスパラギン酸マグネシウムカリウム 0.5％
カオリン ８％
酸化チタン 0.5％
酸化亜鉛 1.5％
ポリアクリル酸ナトリウム ３％
ポリビニルピロリドン・ビニルアセテート共重合
体 ８％
カルボキシメチルセルロース 1.8％
ゼラチン ７％
ソルビタンモノオレエート 0.5％
ポリソルベート80 0.2％
ミリスチン酸イソプロピル １％
インドメタシン １％
サリチル酸メチル 0.5％
dl−メントール 0.5％水 残
合 計 100.0％
実施例 ８
ジヒドロキシアルミニウムアミノアセテート４％
メチルビニルエーテル・無水マレイン酸共重合体
12％
カオリン ８％
ポリビニルアルコール １％
メチルセルロース １％
ポリアクリル酸 ４％
濃グリセリン 15％
70％ソルビトール液 ３％
プロピレングリコール ７％
ゼラチン ３％
ポリブテン ２％
ポリオキシエチレン硬化ヒマシ油 １％
ポリソルベート80 0.5％
イソステアリン酸 １％
インドメタシン １％
ヒアルロン酸 １％
ハツカ油 １％水 残
合 計 100.0％
実施例 ９
アスパラギン酸マグネシウムカリウム ５％
1N−NaOH水溶液 30ml
メトキシエチレン・無水マレイン酸共重合体５％
カオリン 10％
酸化チタン 0.5％
酸化亜鉛 0.5％
ポリビニルピロリドン 1.5％
濃グリセリン 12％
70％ソルビトール ４％
ポリオキシエチレン硬化ヒマシ油 0.5％
ポリソルベート80 １％
サリチル酸メチル ２％
グリチルリチン 0.5％水 残
合 計 100.0％
実施例 10
ジヒドロキシアルミニウムアミノアセテート３％
アスパラギン酸マグネシウムカリウム 1.5％
キサンタンガム 1.5％
ポリアクリル酸ナトリウム ４％
カルボキシビニルポリマー ４％
濃グリセリン ５％
70％ソルビトール液 12％
プロピレングリコール ３％
尿 素 ５％
ポリオキシエチレンソルビタントリオレエート
１％
ポリソルベート80 0.2％
サリチル酸メチル １％
酢酸トコフエロール １％水 残
合 計 100.0％[Table] From the results in Table 3, it is clear that the plaster of the present invention containing an amino acid polyvalent metal salt has better cohesiveness and shape retention than the comparative plaster containing no amino acid polyvalent metal salt. It was recognized that it has excellent properties such as high water retention. Example 3 Dihydroxyaluminum aminoacetate (glycinal) 0.2 parts, kaolin (JP) 5
1 part titanium oxide, polyvinylpyrrolidone (K
-90), 1 part of sodium polyacrylate (Viscomate), and 4 parts of sodium carboxymethyl cellulose (CMC Daicel 2200) are placed in a mixer, and this is mixed with 20 parts of concentrated glycerin (Japanese Pharmacopoeia) and 70% sorbitol solution (Japanese Pharmacopoeia). ) and mix until uniformly dispersed into a paste. Next, a solution obtained by swelling and dissolving 3 parts of polyacrylic acid (Dyurimer AC) in 52.45 parts of water is added to the above paste and kneaded well. Thereafter, 1 part of a surfactant (Polysorbate 80, Japanese Pharmacopoeia) and 1.35 parts of a medicinal ingredient are added to the mixture, and the mixture is kneaded until it becomes uniformly cake-like. In addition, 1.35 parts of medicinal ingredients include 0.5 parts of glycol salicylate (Salimento), 0.2 parts of DL-camphor (Japanese Pharmacopoeia), 0.3 parts of peppermint oil (Japanese Pharmacopoeia), and tocopheryl acetate (Japanese Pharmacopoeia).
0.3 part and diphenhydramine hydrochloride (JP) 0.05
It consists of several parts. Next, this is spread on a nonwoven fabric to a certain thickness using a spreading machine, the surface is covered with a polyethylene film, and cut into a certain area to obtain the poultice of the present invention, which is enclosed in an aluminum foil laminated bag. It was made into a product. The poultice of Example 3 above was used in Example 1 and Comparative Example 1.
As a result of the same tests as in the above, it was found that the plaster had excellent properties such as high cohesiveness, shape retention, and water retention. In addition, the pH of the plaster is
When commercially available poultices that are acidic with a pH of 4.5 and contain the same medicinal ingredients in the same content as the poultices of Example 3 and Example 3 are each stored at 50°C for 10 weeks, the pH of the commercially available poultices is The pH of the poultice in Example 3 increased from 5.3 to 6.3 or higher before storage, and glycol salicylate decomposed and its residual rate was only 10%, indicating a significant decrease in content. 4.5 remained unchanged, and the residual rate of glycol salicylate was 93%, with almost no decomposition observed.The active ingredient is stabilized by maintaining the poultice in an acidic state both during manufacturing and storage. It was recognized that this could be done. Example 4 Dihydroxyaluminum aminoacetate 1% Magnesium potassium aspartate 0.2% Kaolin 5.5% Titanium oxide 0.5% Polyvinyl alcohol 2% Sodium polyacrylate 5% Polyvinylpyrrolidone/vinyl acetate copolymer 6% Carboxyvinyl polymer 1% Concentrated glycerin 24 % Citric acid 0.5% Gelatin 5% Sorbitan monooleate 1% Polyoxyethylene sorbitan monooleate (Polysorbate 80) 2% Isostearic acid 2% Isopropyl myristate 3% Squalane 1% Eucalyptus oil 2% Indomethacin 1% Water Residual total 100.0% Example 5 Dihydroxyaluminum aminoacetate
0.5% Kaolin 12% Zinc oxide 6% Polyvinyl alcohol 5% Sodium polyacrylate 9% Polyvinylpyrrolidone/vinyl acetate copolymer 4% Sodium alginate 1% Polyethylene glycol 400 5% 70% Sorbitol solution 16% Urea 1% Gelatin 8 % Polysorbate 80 1% Horse chestnut extract 0.6% Horse chestnut extract 0.2% Hyaluronic acid 1% Methyl salicylate 1% L-menthol 1% Water Total remaining 100.0% Example 6 Dihydroxyaluminum aminoacetate
0.3% Magnesium potassium aspartate 1% Zinc oxide 1% Polyvinyl alcohol 1% Sodium polyacrylate 4% Polyvinylpyrrolidone/vinyl acetate copolymer 2% Hydroxypropyl cellulose 3% Cyclodextrin 1% Concentrated glycerin 18% Castor oil 1% Propylene Glycol 4% Citric acid 2% Gelatin 9% Polyoxyethylene hydrogenated castor oil 0.6% Polysorbate 80 0.5% Methyl salicylate 1% Glycol salicylate 0.5% Water Remaining total 100.0% Example 7 Magnesium potassium aspartate 0.5% Kaolin 8% Titanium oxide 0.5% Zinc oxide 1.5% Sodium polyacrylate 3% Polyvinylpyrrolidone/vinyl acetate copolymer 8% Carboxymethyl cellulose 1.8% Gelatin 7% Sorbitan monooleate 0.5% Polysorbate 80 0.2% Isopropyl myristate 1% Indomethacin 1% Methyl salicylate 0.5 % dl-menthol 0.5% water Remaining total 100.0% Example 8 Dihydroxyaluminum aminoacetate 4% Methyl vinyl ether/maleic anhydride copolymer
12% Kaolin 8% Polyvinyl alcohol 1% Methyl cellulose 1% Polyacrylic acid 4% Concentrated glycerin 15% 70% Sorbitol solution 3% Propylene glycol 7% Gelatin 3% Polybutene 2% Polyoxyethylene hydrogenated castor oil 1% Polysorbate 80 0.5% Isostearin Acid 1% Indomethacin 1% Hyaluronic acid 1% Peppermint oil 1% Water Remaining total 100.0% Example 9 Magnesium potassium aspartate 5% 1N-NaOH aqueous solution 30ml Methoxyethylene/maleic anhydride copolymer 5% Kaolin 10% Titanium oxide 0.5% Zinc oxide 0.5% Polyvinylpyrrolidone 1.5% Concentrated glycerin 12% 70% Sorbitol 4% Polyoxyethylene hydrogenated castor oil 0.5% Polysorbate 80 1% Methyl salicylate 2% Glycyrrhizin 0.5% Water Remaining total 100.0% Example 10 Dihydroxy aluminum amino Acetate 3% Magnesium Potassium Aspartate 1.5% Xanthan Gum 1.5% Sodium Polyacrylate 4% Carboxyvinyl Polymer 4% Concentrated Glycerin 5% 70% Sorbitol Solution 12% Propylene Glycol 3% Urea 5% Polyoxyethylene Sorbitan Trioleate
1% Polysorbate 80 0.2% Methyl salicylate 1% Tocopheryl acetate 1% Water Total remaining 100.0%
Claims (1)
の多価金属誘導体及び／又はアミノ酸の多価金属
塩を配合してなることを特徴とするパツプ剤。 ２ アミノ酸の多価金属誘導体がジヒドロキシア
ルミニウムアミノアセテートである特許請求の範
囲第１項記載のパツプ剤。 ３ アミノ酸の多価金属塩がアスパラギン酸マグ
ネシウムカリウムである特許請求の範囲第１項記
載のパツプ剤。 ４ アミノ酸の多価金属誘導体及び／又はアミノ
酸の多価金属塩の配合量が膏体全体の0.01〜10重
量％である特許請求の範囲第１項乃至第３項いず
れか記載のパツプ剤。[Scope of Claims] 1. A poultice comprising a plaster containing a water-soluble polymer substance and a polyvalent metal derivative of an amino acid and/or a polyvalent metal salt of an amino acid. 2. The poultice according to claim 1, wherein the polyvalent metal derivative of amino acid is dihydroxyaluminum aminoacetate. 3. The poultice according to claim 1, wherein the polyvalent metal salt of an amino acid is potassium magnesium aspartate. 4. The poultice according to any one of claims 1 to 3, wherein the amount of the polyvalent metal derivative of an amino acid and/or the polyvalent metal salt of an amino acid is 0.01 to 10% by weight of the entire plaster.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11780684A JPS60260513A (en) | 1984-06-08 | 1984-06-08 | Poultice |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11780684A JPS60260513A (en) | 1984-06-08 | 1984-06-08 | Poultice |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60260513A JPS60260513A (en) | 1985-12-23 |
| JPH0338244B2 true JPH0338244B2 (en) | 1991-06-10 |
Family
ID=14720734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11780684A Granted JPS60260513A (en) | 1984-06-08 | 1984-06-08 | Poultice |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60260513A (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2507158B2 (en) * | 1990-08-23 | 1996-06-12 | 積水化学工業株式会社 | Transdermal formulation |
| US5611843A (en) * | 1995-07-07 | 1997-03-18 | Exxon Research And Engineering Company | Membranes comprising salts of aminoacids in hydrophilic polymers |
| JP2001245913A (en) * | 1999-12-28 | 2001-09-11 | Lion Corp | Nonaqueous thermo-gel composition |
| US8697152B2 (en) * | 2005-08-31 | 2014-04-15 | Johnson & Johnson Consumer Companies, Inc. | Anti-inflammatory compositions and personal care compositions comprising olive leaf (Olea europea) extract |
| KR101938919B1 (en) | 2011-07-21 | 2019-01-15 | 데이고꾸세이약꾸가부시끼가이샤 | Water-based plaster |
| JP6418977B2 (en) * | 2015-02-25 | 2018-11-07 | ライオン株式会社 | Transdermal absorption enhancer for patches and non-steroidal anti-inflammatory agents |
| JP7237479B2 (en) * | 2018-06-29 | 2023-03-13 | 小林製薬株式会社 | Gelatin-containing composition |
-
1984
- 1984-06-08 JP JP11780684A patent/JPS60260513A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60260513A (en) | 1985-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102939075A (en) | Transdermal absorption promoter, and external skin formulation thereof | |
| KR100647480B1 (en) | Sheet-form adhesive preparation | |
| JPS6112621A (en) | Cataplasma | |
| JP4596751B2 (en) | Anti-inflammatory analgesic patch | |
| JPH0739748A (en) | Low temperature crosslinked type gel agent | |
| KR20050072459A (en) | Adhesive composition for dermal patch and production process thereof | |
| JP2003070898A (en) | Plaster and production method thereof | |
| JPH0338244B2 (en) | ||
| JPS6158446B2 (en) | ||
| JPS60199832A (en) | Antioxidative pharmaceutical preparation for external use | |
| EP0997144A1 (en) | Plasticizer and patch containing the plasticizer | |
| JP5175041B2 (en) | Hydrophilic adhesive, hydrophilic external skin adhesive composition and hydrophilic patch using the same | |
| US6471984B1 (en) | Cataplasm and tape-aid containing a plasticizer | |
| JPH0338245B2 (en) | ||
| JPS6034924B2 (en) | Poultice and its manufacturing method | |
| JPH0749050B2 (en) | Hydrous gel composition | |
| JPH0333686B2 (en) | ||
| JPS6112614A (en) | Drug for external use | |
| JPH0339043B2 (en) | ||
| JPH0336806B2 (en) | ||
| JP3145857B2 (en) | Aqueous warming patch | |
| JPS5843365B2 (en) | Hydrophilic poultice | |
| JP2004196705A (en) | Cataplasm | |
| JPH10265374A (en) | External agent composition and its production | |
| JPS5953411A (en) | Base for poultice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |